DiaSorin Completes $1.8bn Acquisition Of Luminex
The brokered deal will broaden DiaSorin’s offerings in the rapidly growing liquid diagnostics market, while also providing Luminex furthered access to markets outside of the US.
You may also be interested in...
During the second quarter of 2021, device company M&A values reached $2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $4.4bn.
The buyout will broaden DiaSorin’s positioning in the fast-growing molecular diagnostics space and expand Luminex’s foothold outside the US.
Embecta, which recently completed its spin-off from Becton Dickinson, is forging ahead with its insulin injector-based business strategy, GLP-1s be damned.